PORRO, ALBERTO
 Distribuzione geografica
Continente #
NA - Nord America 611
EU - Europa 418
AS - Asia 66
AF - Africa 22
SA - Sud America 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.122
Nazione #
US - Stati Uniti d'America 611
GB - Regno Unito 128
IT - Italia 66
SE - Svezia 61
DE - Germania 59
CN - Cina 40
IE - Irlanda 22
IN - India 21
FR - Francia 20
RU - Federazione Russa 19
UA - Ucraina 15
EE - Estonia 11
ZA - Sudafrica 10
CH - Svizzera 6
TG - Togo 6
CI - Costa d'Avorio 4
BG - Bulgaria 3
BE - Belgio 2
BR - Brasile 2
DK - Danimarca 2
NL - Olanda 2
CL - Cile 1
CZ - Repubblica Ceca 1
EC - Ecuador 1
EU - Europa 1
IR - Iran 1
JP - Giappone 1
NG - Nigeria 1
NO - Norvegia 1
SA - Arabia Saudita 1
SC - Seychelles 1
SG - Singapore 1
TR - Turchia 1
Totale 1.122
Città #
Fairfield 115
Southend 115
Chandler 59
Ashburn 45
Woodbridge 39
Wilmington 38
Seattle 33
Cambridge 29
Houston 27
Ann Arbor 24
Princeton 24
Dublin 22
New York 22
Bologna 13
Bremen 12
Saint Petersburg 11
Westminster 11
Medford 10
Dearborn 9
Nanjing 9
Jacksonville 6
Lomé 6
Berlin 5
Boardman 5
Padova 5
San Diego 5
Abidjan 4
Changsha 4
Bolzano 3
Hebei 3
Jinan 3
Kunming 3
Pune 3
Redwood City 3
Shenyang 3
Sofia 3
Taizhou 3
Tianjin 3
Bern 2
Brussels 2
Florence 2
Jiaxing 2
Milan 2
Nanchang 2
Norwalk 2
Olalla 2
São Paulo 2
Abeokuta 1
Ardabil 1
Beijing 1
Buffalo 1
Castelfidardo 1
Chengdu 1
Den Haag 1
Des Moines 1
Falls Church 1
Fermo 1
Frankfurt Am Main 1
Frattamaggiore 1
Fuzhou 1
Groningen 1
Guangzhou 1
Las Vegas 1
Mülheim 1
Orange 1
Oslo 1
Pignone 1
Quito 1
Radeberg 1
San Francisco 1
Singapore 1
Tallinn 1
Washington 1
Totale 781
Nome #
The future of dual therapy for hepatitis C virus 156
Correlation between Indocyanine green retention test and esophageal varices among patients with hepatocellular carcinoma 119
IL28 polymorphism and HCC after DAAs for chronic hepatitis C 112
P.09.6 IL28 POLYMORPHISM AND HCC DEVELOPMENT AFTER DAAS FOR CHRONIC HEPATITIS C 102
Spleen stiffness measurement: A useful prognostic tool in HCV patients treated with DAAs regimens 101
null 96
Indocyanine green clearance (ICG) as a predictor of 2-years clinical decompensation and mortality in patients with compensated liver cirrhosis 82
THU-490 - Spleen stiffness measurement: a useful prognostic tool in HCV patients treated with DAAs regimens 81
Indocyanine Green 15-min Retention test (ICG-r15) as a predictor of clinical decompensation in patients with compensated liver cirrhosis. 79
Indocyanine Green Clearance (ICG) as a predictor of clinical decompensation and mortality in patients with compensated liver cirrhosis 78
Indocyanine green retention test predict the risk of portal hypertension-related events after direct-acting antiviral therapy in compensated advanced chronic liver disease patients 64
Indocyanine green clearance (ICG) as a predictor of clinical decompensation and mortality in patients with compensated liver cirrhosis. 59
Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older 36
Totale 1.165
Categoria #
all - tutte 3.026
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.026


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020298 44 8 1 18 35 32 46 39 36 15 11 13
2020/2021140 30 14 6 4 6 4 6 9 22 14 9 16
2021/2022281 11 6 17 16 23 9 7 16 9 18 111 38
2022/2023224 25 29 12 36 18 22 8 9 42 5 14 4
2023/202477 1 13 1 10 4 34 5 0 4 3 0 2
2024/20251 1 0 0 0 0 0 0 0 0 0 0 0
Totale 1.165